Biotech RadarJobs updated

COMPANY

Sana Biotechnology

HQ: Seattle, WA source · sana.com ↗ · West Coast

Clinical Phase 1

Keywords: metabolic type 1 diabetes Non Hodgkin's Lymphoma Large B-cell Lymphoma Lupus Erythematosus Systemic Lupus Erythematosus SLE (Systemic Lupus) Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Granulomatous Polyangiitis Microscopic Polyangiitis Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia SC291 SC262

Location: Seattle, WA · source · Sep 8, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) source ↗
  2. Trial start Phase 1: Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) source ↗
  3. Trial start Phase 1: Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT06285422Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)Phase 1Active, not recruitingApr 18, 20242025-12 (estimated)
NCT06294236Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)Phase 1Active, not recruitingApr 29, 20242027-12 (estimated)
NCT05878184Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)Phase 1Active, not recruitingMay 2, 2023Nov 4, 2025 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback